Aligos Therapeutics (ALGS) Total Non-Current Liabilities (2019 - 2024)

Aligos Therapeutics has reported Total Non-Current Liabilities for 6 years, with the latest figure at $26.7 million in Q4 2024.

• For the quarter ending Q4 2024, Total Non-Current Liabilities fell 16.17% year-over-year to $26.7 million; the trailing twelve-month figure through Dec 2024 stood at $26.7 million (down 16.17% YoY), and the FY2024 full-year result was $26.7 million, down 16.17% from the prior year.
• Total Non-Current Liabilities for Q4 2024 stood at $26.7 million, roughly flat from $26.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $57.4 million in Q1 2022, with the low at $26.1 million in Q1 2024.
• Historically, Total Non-Current Liabilities has averaged $39.7 million across 5 years, with a median of $42.3 million in 2021.
• Annual changes were most pronounced in 2020 — Total Non-Current Liabilities jumped 56.78% — and 2024, when it retreated 16.17%.
• Aligos Therapeutics' Total Non-Current Liabilities stood at $45.3 million in 2020, then advanced by 11.58% to $50.5 million in 2021, then declined by 16.99% to $41.9 million in 2022, then slipped by 24.02% to $31.9 million in 2023, then dropped by 16.17% to $26.7 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $26.7 million (Q4 2024), $26.7 million (Q3 2024), and $30.1 million (Q2 2024), per Business Quant data.